-
From Later Lines to Front Lines, New ADCs Bring Survival Benefits to More Patients with HER2 Overexpression and HER2 Ultra-Low Expression
The mid-year meeting of the Youth Expert Committee of the Chinese Society of Clinical Oncology (CSCO YOUNG) was held from June 28-30, 2024, in Shanghai, where young elites from across the country gathered to discuss academic progress. Recent updates and announcements from various DESTINY-Breast (DB) series studies have brought more benefits to patients with HER2-positive,…
-
Professor Simon J. Crabb: Evaluating Self-Help CBT for Hot Flushes and Night Sweats in Prostate Cancer Patients on ADT in the MANCAN2 Study
ASCO International Perspective | experience hot flushes and night sweats (HFNS), which not only decrease their quality of life but may also affect compliance with ADT. Current relief methods are limited. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Simon J. Crabb from the University Hospital Southampton presented the results of…
-
BOC/BOA 2024 | Professor Tian Yang: Annual Advances in Chinese Clinical Oncology 2023 (Hepatobiliary and Pancreatic Tumors)
Since 2015, the Chinese Society of Clinical Oncology (CSCO) has adhered to the philosophy of “International Standards, Chinese Characteristics, Learning and Absorbing, Innovating and Improving,” launching the “Annual Research Advances in Chinese Clinical Oncology” for nine consecutive years. At the recently held “2024 Annual Progress Seminar on Chinese Clinical Oncology (BOC) and Best of ASCO…
-
Professor Qing Xie: Contributions and Challenges of Long-Acting Interferon in the Clinical Cure of Chronic Hepatitis B
Antiviral treatment can maximize the long-term suppression of hepatitis B virus (HBV) DNA replication, reducing liver necrosis, fibrosis, cirrhosis, liver cancer, and other complications, thereby improving the quality of life and extending the survival time of hepatitis B patients. Currently, long-acting interferon is recommended as a first-line treatment option by guidelines in Europe, the United…
-
APACC2024 | Dr. Chunyan Li: Service Provision and Adherence Support for HIV Pre-Exposure Prophylaxis (PrEP)
Numerous studies have explored the use of long-acting antiretroviral therapy (Long-acting ART) for HIV pre-exposure prophylaxis (PrEP), achieving positive preventive outcomes. However, the promotion of long-acting PrEP still faces many challenges. Additionally, how can adherence to existing oral PrEP regimens be further improved? At the recently held 9th Asia Pacific AIDS & Co-infections Conference (APACC…
-
Exempting RNI in Post-BCS pN1 Breast Cancer Patients Who Have Undergone Taxane-Based Chemotherapy
For most patients, postoperative radiotherapy plays a crucial role. Some early-stage breast cancer patients require prophylactic regional lymph node irradiation (RNI) in addition to whole-breast irradiation (WBI). However, the survival benefit of RNI for patients with 1-3 positive axillary lymph nodes (pN1) remains uncertain. Therefore, it’s necessary to evaluate the impact of RNI on the…
-
Standardized Diagnosis and Treatment with Innovative Breakthroughs, Ushering in a Golden Era for China’s Hematologic Oncology Field
From July 5 to 7, 2024, the highly anticipated 2024 Annual Progress Seminar on Chinese Clinical Oncology (BOC) and Best of ASCO 2024 China was grandly held in Guangzhou. The conference focused on the “Annual Research Advances in Chinese Clinical Oncology 2023,” selected by the Chinese Society of Clinical Oncology (CSCO), aiming to delve into…
-
ASCO International Perspective | Professor Samuel R. Denmeade: Biomarkers for Bipolar Androgen Therapy in mCRPC
The 2024 American Society of Clinical Oncology (ASCO) Annual Meeting concluded successfully. In a recent late-breaking abstract (LBA) report, Professor Samuel R. Denmeade from Johns Hopkins University School of Medicine shared the specific results of the TRANSFORMER trial. This randomized trial targeted abiraterone-pretreated metastatic castration-resistant prostate cancer (mCRPC) patients, aiming to identify blood biomarkers. “Oncology…
Connecting Medical Expertise through Media